Central sensitization in chronic back pain manifested as greater unpleasantness to both pressure and sound, with stronger and more specific amplification for auditory stimuli than mechanical ...
A TOPOGRAPH-based hierarchy stratifies biomarker–drug pairs from regulatory/positive trial evidence (tiers 1–3A) to repurposing across histotypes (3B), preclinical/early data (4), and suspected ...
Lynavoy is used to treat cholestatic pruritus, an extreme itch that affects almost 90% of patients with primary biliary cholangitis.
Retrospective, single-center design and limited power render findings hypothesis-generating, supporting prospective ...
Federal grant delays, cancellations, and rescissions are curtailing HIV testing, surveillance, and community engagement, compounded by reduced CDC surveillance activity and an HIV workforce unable to ...
Postdischarge adverse drug event risk is amplified by frequent medication changes, formulary substitutions, and insurance coverage gaps, with wide variability in published incidence estimates and ...
L1, EBV and mismatch repair deficiency suggests CLDN18.2 stratification must be integrated into multi-biomarker algorithms rather than used in isolation. Treatment interactions emerged: CLDN18.2-high ...
Guardant Health markets Shield, an FDA-approved blood test for primary colorectal cancer screening. The Harris Poll conducted the survey from Feb. 24-26, 2026, among 1,189 U.S. adults, ages 45 and ...
PREVENT risk estimation starts at age 30 and incorporates lifetime risk, enabling earlier identification of patients who warrant intensified lipid management and preventive therapies. LDL-C treatment ...
This month, the Florida Department of Health dramatically reduced the eligibility for their AIDS Drug Assistance Program ...
FDA approval covers adults and adolescents ≥12 years (≥88 lbs) with moderate-to-severe plaque psoriasis requiring systemic therapy or phototherapy, expanding systemic options beyond injectables.
Fiscal stress reflects rates lagging medical trend; behavioral health utilization far exceeded assumptions (30% vs 3.5%–4%), ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results